FDA approved a new formulation for PYLARIFY to increase batch sizes, and NEURACEQ sales recently jumped from $20 million to $31 million quarter-over-quarter. The new PYLARIFY formulation will expand geographic reach, while the growing US dementia crisis will turn NEURACEQ into a blockbuster product, driving significant revenue. Buy LNTH as an undervalued biotech play with a proven sales team and highly successful medical imaging products. Slower than expected adoption of NEURACEQ, competition from other imaging agents, or unforeseen regulatory hurdles.
LNTH
HIGH
Mar 09, 15:27
Key Points
['LNTH is an undervalued biotech cash cow.', 'PYLARIFY is the #1 prostate cancer imaging agent.', 'New PYLARIFY formulation expands market reach.', 'NEURACEQ sales grew from $20M to $31M recently.', 'Dementia crisis provides massive TAM for NEURACEQ.']
March 09, 2026 at 15:27